Sissetulev kiriAvalik
Farmakopöa tööplaani asjus
Ravimiamet · 17. mai 2024
- Viit
- REP-1/1809-1
- Registreeritud
- 17. mai 2024
- Dokumendi liik
- Sissetulev kiri
- Adressaat
- European Directorate for the Quality of Medicines & HealthCare
- Saabumis/saatmisviis
- e-post
- Funktsioon
- REP Euroopa Farmakopöaga seotud asjaajamine
- Sari
- REP-1 Euroopa Farmakopöa alane kirjavahetus
- Toimik
- REP-1/2024
- Vastutaja
- Signe Leito (RA, Labor)
Sisu (failidest)
Signe Leito
Saatja: [email protected]
Saatmisaeg: reede, 26. aprill 2024 15:39
Adressaat: Signe Leito
Teema: For action: Proposed addition to the work programme of Group 17 - Sitagliptin malate: EDQM-2024-01782-mail
Tähelepanu! Tegemist on väljastpoolt asutust saabunud kirjaga. Tundmatu saatja korral palume linke ja faile mitte avada.
Please make sure to include in any reply our mail reference: EDQM-2024-01782-mail
****************************************************************************
For the attention of NPAs
Copy: Presidium
Dear Colleagues,
Please find below the link to a survey being carried out concerning the proposed addition of Sitagliptin malate to the work programme of Group 17.
In order to have access to the survey, please copy and paste the link into your Internet browser:
https://survey.edqm.eu/index.php?r=survey/index&sid=733794&newtest=Y&lang=en
Deadline for replies: 29 May 2024
Thank you.
With kind regards
On behalf of Isabelle Mercier
Villy Nikolova
Administrative Support Assistant
European Pharmacopoeia Department
EDQM
Council of Europe
Tel.: +33 (0)3 90 21 64 63 / Fax: +33 (0)3 88 41 27 71
https://www.edqm.eu / https://www.edqm.eu/store
Stay connected with the EDQM
1
****************************************************************************
Please make sure to include in any reply our mail reference: EDQM-2024-01782-mail
2